Literature DB >> 33191288

Hospitalization Rates Are Highest in the First 5 Years of Systemic Sclerosis: Results From a Population-based Cohort (1980-2016).

Caitrin M Coffey1, Avneek S Sandhu2, Cynthia S Crowson3, Sara J Achenbach4, Eric L Matteson3, Thomas G Osborn1, Kenneth J Warrington1, Ashima Makol5.   

Abstract

OBJECTIVE: Few studies have estimated the healthcare resource usage of patients with systemic sclerosis (SSc). The purpose of this study was to compare hospitalization among incident cases of SSc vs age- and sex-matched comparators.
METHODS: A retrospective, population-based cohort of patients with SSc in Olmsted County, Minnesota, from January 1, 1980, to December 31, 2016, was assembled. A 2:1 cohort of age- and sex-matched patients without SSc from the same population was randomly selected for comparison. All hospitalizations in the geographic area from January 1, 1987, to September 30, 2018, were obtained. Rates of hospitalization, lengths of stay, and readmissions were compared between groups.
RESULTS: There were 76 incident SSc cases and 155 non-SSc comparators (mean age 56 ± 16 yrs at diagnosis/index, 91% female) included. Rates of hospitalization among cases and comparators were 31.9 and 17.9 per 100 person-years, respectively (rate ratio [RR] 1.78, 95% CI 1.52-2.08). Hospitalization rates were higher in patients with SSc than comparators during the first 5 years after SSc diagnosis (RR 2.16, 95% CI 1.70-2.74). This difference decreased over time and was no longer significant at ≥ 15 years after SSc incidence/index. Lengths of stay (median [IQR] 4 [2-6] vs 3 [2-6], P = 0.52) and readmission rates (25% vs 23%, P = 0.51) were similar between groups.
CONCLUSION: Patients with SSc were hospitalized more frequently than comparators, indicating high inpatient care needs in this population. Hospitalization rates were highest during the first 5 years following SSc diagnosis.
Copyright © 2021 by the Journal of Rheumatology.

Entities:  

Keywords:  facilities and services utilization; hospitalization; systemic sclerosis

Mesh:

Year:  2020        PMID: 33191288      PMCID: PMC8121887          DOI: 10.3899/jrheum.200737

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   5.346


  13 in total

Review 1.  Mortality and survival in systemic sclerosis: systematic review and meta-analysis.

Authors:  Manuel Rubio-Rivas; Cristina Royo; Carmen Pilar Simeón; Xavier Corbella; Vicent Fonollosa
Journal:  Semin Arthritis Rheum       Date:  2014-05-14       Impact factor: 5.532

2.  Hospitalization rates and utilization among patients with giant cell arteritis: A population-based study from 1987 to 2012.

Authors:  Clement John Michet; Sara J Achenbach; Cynthia S Crowson; Eric L Matteson
Journal:  Semin Arthritis Rheum       Date:  2015-03-03       Impact factor: 5.532

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  Hospital admissions, length of stay, charges, and in-hospital death among patients with systemic sclerosis.

Authors:  P J Nietert; M D Silverstein; R M Silver
Journal:  J Rheumatol       Date:  2001-09       Impact factor: 4.666

5.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.

Authors:  Anthony J Tyndall; Bettina Bannert; Madelon Vonk; Paolo Airò; Franco Cozzi; Patricia E Carreira; Dominique Farge Bancel; Yannick Allanore; Ulf Müller-Ladner; Oliver Distler; Florenzo Iannone; Raffaele Pellerito; Margarita Pileckyte; Irene Miniati; Lidia Ananieva; Alexandra Balbir Gurman; Nemanja Damjanov; Adelheid Mueller; Gabriele Valentini; Gabriela Riemekasten; Mohammed Tikly; Laura Hummers; Maria J S Henriques; Paola Caramaschi; Agneta Scheja; Blaz Rozman; Evelien Ton; Gábor Kumánovics; Bernard Coleiro; Eva Feierl; Gabriella Szucs; Carlos Alberto Von Mühlen; Valeria Riccieri; Srdan Novak; Carlo Chizzolini; Anna Kotulska; Christopher Denton; Paulo C Coelho; Ina Kötter; Ismail Simsek; Paloma García de la Pena Lefebvre; Eric Hachulla; James R Seibold; Simona Rednic; Jirí Stork; Jadranka Morovic-Vergles; Ulrich A Walker
Journal:  Ann Rheum Dis       Date:  2010-06-15       Impact factor: 19.103

6.  Hospitalization Among Patients with Sarcoidosis: A Population-Based Cohort Study 1987-2015.

Authors:  Patompong Ungprasert; Cynthia S Crowson; Sara J Achenbach; Eva M Carmona; Eric L Matteson
Journal:  Lung       Date:  2017-04-29       Impact factor: 2.584

7.  Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample.

Authors:  L Chung; E Krishnan; E F Chakravarty
Journal:  Rheumatology (Oxford)       Date:  2007-11-06       Impact factor: 7.580

Review 8.  Humanistic and cost burden of systemic sclerosis: A review of the literature.

Authors:  Aryeh Fischer; Evelina Zimovetz; Caroline Ling; Dirk Esser; Nils Schoof
Journal:  Autoimmun Rev       Date:  2017-09-09       Impact factor: 9.754

9.  Mortality, length of stay and cost of hospitalization among patients with systemic sclerosis: results from the National Inpatient Sample.

Authors:  Dilli Ram Poudel; Michael George; Rashmi Dhital; Paras Karmacharya; Nora Sandorfi; Chris T Derk
Journal:  Rheumatology (Oxford)       Date:  2018-09-01       Impact factor: 7.580

10.  Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes.

Authors:  Christine Peoples; Thomas A Medsger; Mary Lucas; Bedda L Rosario; Carol A Feghali-Bostwick
Journal:  J Scleroderma Relat Disord       Date:  2016-07-23
View more
  1 in total

1.  Hospital readmission in systemic sclerosis associated pulmonary hypertension: Results from the PHAROS registry.

Authors:  Kimberly Showalter; Laura C Pinheiro; Deanna Jannat-Khah; Irina Sobol; Jackie Szymonifka; Jackie Finik; Virginia D Steen; Jessica K Gordon
Journal:  Rheumatology (Oxford)       Date:  2022-04-11       Impact factor: 7.046

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.